- Home
- SGML vs BCAX Comparison
SGML vs BCAX Comparison
Compare SGML & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- BCAX
- Stock Information
- Founded
- SGML 2011
- BCAX 2018
- Country
- SGML Brazil
- BCAX United States
- Employees
- SGML N/A
- BCAX N/A
- Industry
- SGML Industrial Machinery/Components
- BCAX
- Sector
- SGML Industrials
- BCAX
- Exchange
- SGML Nasdaq
- BCAX NYSE
- Market Cap
- SGML 518.6M
- BCAX 487.6M
- IPO Year
- SGML N/A
- BCAX 2024
- Fundamental
- Price
- SGML $5.44
- BCAX $9.71
- Analyst Decision
- SGML Strong Buy
- BCAX Strong Buy
- Analyst Count
- SGML 2
- BCAX 7
- Target Price
- SGML $18.00
- BCAX $29.17
- AVG Volume (30 Days)
- SGML 2.1M
- BCAX 675.0K
- Earning Date
- SGML 08-14-2025
- BCAX 08-16-2025
- Dividend Yield
- SGML N/A
- BCAX N/A
- EPS Growth
- SGML N/A
- BCAX N/A
- EPS
- SGML N/A
- BCAX N/A
- Revenue
- SGML $152,515,393.00
- BCAX N/A
- Revenue This Year
- SGML $43.73
- BCAX N/A
- Revenue Next Year
- SGML $130.53
- BCAX N/A
- P/E Ratio
- SGML N/A
- BCAX N/A
- Revenue Growth
- SGML 0.36
- BCAX N/A
- 52 Week Low
- SGML $4.25
- BCAX $7.80
- 52 Week High
- SGML $15.56
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- SGML 52.92
- BCAX N/A
- Support Level
- SGML $4.94
- BCAX N/A
- Resistance Level
- SGML $5.95
- BCAX N/A
- Average True Range (ATR)
- SGML 0.39
- BCAX 0.00
- MACD
- SGML 0.18
- BCAX 0.00
- Stochastic Oscillator
- SGML 70.00
- BCAX 0.00
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.